Menu

NIH’s Neuroscience Institute Plans to Limit Financial Support for Well-Funded Investigators

Under a new policy, the National Institute of Neurological Disorders and Stroke will provide fewer grants to labs receiving more than $1 million in funds.

May 3, 2018
Diana Kwon

NCI, CHRIS SPIELMANN

The National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH), will limit the number of grants it provides to well-funded investigators, according to a new policy it announced last week (April 27).

In 2012, the NIH implemented an institutes-wide policy under which grant applications from investigators already receiving more than $1 million in funding would receive additional scrutiny. The new NINDS rules, which will apply to grants under consideration from January 2019 and beyond, will extend the stricter review to labs whose funding support would exceed $1 million after the acceptance of a pending proposal.

The policy “will allow us to fund more early stage investigators and help people who just missed the pay line [funding cutoff] and are about to drop off the radar screen,” Robert Finkelstein, the extramural research director at NINDS, tells Science.

See “Proposed NIH Grant Cap Criticized

Last year, the NIH proposed a grant cap, based on its funding metric called the Grant Support Index (GSI), for investigators who received more than three R01 grants, in order to provide more funding opportunities for early-career researchers. However, after drawing heavy criticism from the research community, the NIH decided to abandon that plan and instead created the Next Generation Researchers Initiative, a special fund for early- to mid-career investigators.

“When the GSI went away the problem of funding more investigators didn’t disappear. So something has to be done to fund more people,” Howard Garrison, director of public affairs at the Federation of American Societies for Experimental Biology, tells Science.

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.